  In this special edition of the View, Dr. Eagle summarizes the top science that will be presented at TCT 2023 from October 23rd to October 26th in San Francisco.     Dr. Eagle shares some of the trials that have captured attention, including: Four Year Outcomes from the EVOLUT Low Risk Trial, Five-Year Clinical and Echocardiographic Outcomes from the PARTNER 3 Low Risk Randomized Trial, Less-Than One-Month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy After Coronary Drug Eluting Stent Implantation for Acute Coronary Syndrome, TRISCEND II: A Randomized Trial of Transcatheter Tricuspid Valve Replacement, and Individual Patient Data Pooled Analysis of Endovascular Ultrasound Renal Denervation.     These trials hold significant promise for advancing the field of interventional cardiology, of Eagle’s Eye View looks forward to reviewing the results at TCT 2023.      There will be daily updates giving more details on these trials and more.     Subscribe to Eagle’s Eye View   

Eagle’s Eye View: TCT 2023 Preview

The weekly cardiovascular update from ACC.org Editor-in-Chief Kim Eagle, MD, MACC, covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.

Education

Training

Language Courses

Higher Education

K-12

Educational Technology

Medicine

Science & Medicine

Health & Fitness

 In this week’s View, Dr. Eagle looks at the diagnostic value of aortic valve calcification levels in the assessment of low-gradient aortic stenosis.        He then examines the prognostic value of microvascular resistance reserve after percutaneous coronary intervention in patients with myocardial infarction.        Finally, Dr. Eagle shares some thoughts on clinical outcomes associated with various microvascular injury patterns identified by cardiac MRI after STEMI.    Subscribe to Eagle’s Eye View   

Aortic Valve Calcification and Aortic Stenosis, Microvascular Resistance Reserve After PCI, Microvascular Injury Patterns

 In this week’s View, Dr. Eagle looks at transcatheter-based intervention for tetraology of Fallot. He then examines how a small left ventricle in patients with atrial fibrillation is associated with increased cardiovascular risk. Finally, Dr. Eagle shares some thoughts on an aspirin-free strategy for immediate treatment following complex percutaneous coronary intervention.    Subscribe to Eagle’s Eye View   

Transcatheter-Based Intervention and Tetralogy of Fallot, Small Left Ventricle and Atrial Fibrillation (Afib), Aspirin Free Treatment Post-PCI

 In this week’s View, Dr. Eagle looks at the recently released guidelines for lower extremity peripheral arterial disease (PAD). He then examines a national community-based cohort study on contemporary decongestion strategies in patients hospitalized for heart failure. Finally, Dr. Eagle shares some thoughts on the implications of discordance among ApoB, non–high-density lipoprotein cholesterol and triglycerides for cardiovascular prevention.    Subscribe to Eagle’s Eye View   

Guideline for the Management of Lower Extremity Peripheral Artery Disease (PAD), Decongestion Strategies for Heart Failure, Lipoproteins and Triglycerides in Cardiovascular Prevention

 In this week’s View, Dr. Eagle looks at the new AHA/ACC Hypertrophic Cardiomyopathy Guideline, then examines a randomized clinical trial that studied smoking cessation after initial treatment failure with varenicline or nicotine. Finally, Dr. Eagle shares some thoughts on a clinical consensus statement of the ESC Council on Stroke, the European Association of Cardiovascular Imaging, and the European Heart Rhythm Association of the ESC on embolic strokes of an undetermined source.    Subscribe to Eagle’s Eye View   

Eagle’s Eye View: The New AHA/ACC Hypertrophic Cardiomyopathy Guideline, Smoking Cessation, Embolic Stroke

 In this week’s View, Dr. Eagle looks at the durability of pulmonary vein isolation using pulsed-field ablation, then examines genetic penetrance of dilated cardiomyopathy in genotype-positive relatives. Finally, Dr. Eagle shares some thoughts on reinterventions after CoreValve/Evolut TAVR or SAVR for treatment of severe aortic stenosis.    Subscribe to Eagle’s Eye View   

Eagle’s Eye View: Pulsed Field Ablation and Pulmonary Vein Isolation, Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives, TAVR or SAVR and Severe Aortic Stenosis

Eagle’s Eye View: TCT 2023 Preview

Download our free app to listen on your phone